Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV.

Research square·2026

Same author

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

medRxiv : the preprint server for health sciences·2026

Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Same author

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

JACC. Advances·2026

Same author

Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study.

Acta haematologica·2026

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Aaron T Gerds¹, Jason Gotlib², Peter Abdelmessieh³

¹1Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Journal of the National Comprehensive Cancer Network : JNCCN

|July 9, 2026

Summary

NCCN Guidelines offer updated recommendations for Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), focusing on myelofibrosis care. These insights reflect expert consensus on managing these heterogeneous hematologic malignancies.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Experiment Videos

Last Updated: Jul 12, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Area of Science:

Hematology
Oncology
Clinical Guidelines

Background:

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) encompass myelofibrosis, polycythemia vera, and essential thrombocythemia.
These are heterogeneous hematologic malignancies characterized by abnormal blood cell proliferation.

Purpose of the Study:

To provide updated, comprehensive care recommendations for adult patients with MPNs.
To focus on recent advancements and guideline changes specifically for myelofibrosis.

Main Methods:

Development of NCCN Guidelines by a multidisciplinary panel of MPN experts.
Annual meetings to review requested changes and evaluate emerging scientific data.

Main Results:

Recent updates to the NCCN Guidelines for MPN, with a specific focus on myelofibrosis management.
Incorporation of new data and expert consensus into clinical recommendations.

Conclusions:

The updated guidelines aim to enhance the comprehensive care of adults with myelofibrosis and other Philadelphia chromosome-negative MPNs.
Regular evaluation of emerging data ensures guidelines remain current for these complex hematologic malignancies.